Read her highlights and what they mean for your business: #TOPRASymposium #RegulatoryAffairs #Pharma #EURegulations #MHRA #Compliance #PartnerOfChoice To view or add a comment, sign in One month on, Nicola Gover shares her lasting insights from this years TOPRA - The Organisation for Professionals in Regulatory Affairs Symposium in Berlin
Standard of Care) study for alogliptin (58, 62), the Savor-TIMI-53 study (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53) for saxagliptin (60, 63), the TECOS study (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) for sitagliptin (59, 64) and the CARMELINA study (Cardiovascular safety and Clinical Outcome with Linagliptin) for linagliptin (61, 65)
Variability in plant origin, cultivation conditions, harvest time, and processing methods often leads to inconsistencies in bioactive compound concentrations, thereby complicating doseresponse evaluation
Saxagliptin has significant drug interactions because it is extensively metabolized by CYP 3A4/5 and to a lesser extent CYP 2C8 in the liver (Dave, 2011)
doi: 10.5195/cajgh.2016.241 113 KulkarniSSMishraSPatilSBNambiarJMathA
Oxidatively generated damage to cellular DNA by UVB and UVA radiation